{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:47:06Z","timestamp":1791362826871,"version":"4.3.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,5,11]],"date-time":"2018-05-11T00:00:00Z","timestamp":1525996800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s00467-018-3970-y","type":"journal-article","created":{"date-parts":[[2018,5,10]],"date-time":"2018-05-10T20:31:44Z","timestamp":1525984304000},"page":"2253-2265","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Mycophenolate mofetil for sustained remission in nephrotic syndrome"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6783-3822","authenticated-orcid":false,"given":"Uwe","family":"Querfeld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz T.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,11]]},"reference":[{"key":"3970_CR1","doi-asserted-by":"crossref","unstructured":"Hodson EM, Willis NS, Craig JC (2008) Non-corticosteroid treatment for nephrotic syndrome in children. Cochrane Database Syst Rev:CD002290","DOI":"10.1002\/14651858.CD002290.pub3"},{"key":"3970_CR2","doi-asserted-by":"crossref","unstructured":"Pravitsitthikul N, Willis NS, Hodson EM, Craig JC (2013) Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children. Cochrane Database Syst Rev:CD002290","DOI":"10.1002\/14651858.CD002290.pub4"},{"key":"3970_CR3","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/kisup.2012.9","volume":"2","author":"Group KDIGOKGW","year":"2012","unstructured":"Group KDIGOKGW (2012) KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl 2:139\u2013274","journal-title":"Kidney Int Suppl"},{"key":"3970_CR4","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s00112-017-0309-x","volume":"165","author":"U Querfeld","year":"2017","unstructured":"Querfeld U, D\u00f6tsch J, Gellermann J, Hoyer P, Kemper M, Latta K, T\u00f6nshoff B, Weber LT, Rascher W (2017) Diagnosis and therapy of idiopathic nephrotic syndrome in childhood. Summary of the S2e guideline AWMF registry number 166-001, headed by the German Society for Pediatric Nephrology. Monatsschr Kinderheilkd 165:997\u20131004","journal-title":"Monatsschr Kinderheilkd"},{"key":"3970_CR5","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00467-012-2310-x","volume":"28","author":"RM Lombel","year":"2013","unstructured":"Lombel RM, Gipson DS, Hodson EM, Kidney Disease: Improving Global O (2013) Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO. Pediatr Nephrol 28:415\u2013426","journal-title":"Pediatr Nephrol"},{"key":"3970_CR6","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.1097\/01.tp.0000186390.10150.66","volume":"80","author":"AC Allison","year":"2005","unstructured":"Allison AC, Eugui EM (2005) Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation 80:S181\u2013S190","journal-title":"Transplantation"},{"key":"3970_CR7","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.neuint.2009.12.003","volume":"56","author":"M Camici","year":"2010","unstructured":"Camici M, Micheli V, Ipata PL, Tozzi MG (2010) Pediatric neurological syndromes and inborn errors of purine metabolism. Neurochem Int 56:367\u2013378","journal-title":"Neurochem Int"},{"key":"3970_CR8","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/nrneph.2012.215","volume":"8","author":"BH Rovin","year":"2012","unstructured":"Rovin BH (2012) Lupus nephritis: guidelines for lupus nephritis--more recommendations than data? Nat Rev Nephrol 8:620\u2013621","journal-title":"Nat Rev Nephrol"},{"key":"3970_CR9","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1007\/s12026-014-8609-x","volume":"60","author":"F Conti","year":"2014","unstructured":"Conti F, Ceccarelli F, Perricone C, Massaro L, Cipriano E, Pacucci VA, Truglia S, Miranda F, Morello F, Alessandri C, Spinelli FR, Valesini G (2014) Mycophenolate mofetil in systemic lupus erythematosus: results from a retrospective study in a large monocentric cohort and review of the literature. Immunol Res 60:270\u2013276","journal-title":"Immunol Res"},{"key":"3970_CR10","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1681\/ASN.V9112055","volume":"9","author":"R Ziswiler","year":"1998","unstructured":"Ziswiler R, Steinmann-Niggli K, Kappeler A, Daniel C, Marti HP (1998) Mycophenolic acid: a new approach to the therapy of experimental mesangial proliferative glomerulonephritis. J Am Soc Nephrol 9:2055\u20132066","journal-title":"J Am Soc Nephrol"},{"key":"3970_CR11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1093\/ndt\/14.1.58","volume":"14","author":"IA Hauser","year":"1999","unstructured":"Hauser IA, Renders L, Radeke HH, Sterzel RB, Goppelt-Struebe M (1999) Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion. Nephrol Dial Transplant 14:58\u201363","journal-title":"Nephrol Dial Transplant"},{"key":"3970_CR12","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1046\/j.1523-1755.2002.00514.x","volume":"62","author":"I Dubus","year":"2002","unstructured":"Dubus I, Vendrely B, Christophe I, Labouyrie JP, Delmas Y, Bonnet J, Combe C (2002) Mycophenolic acid antagonizes the activation of cultured human mesangial cells. Kidney Int 62:857\u2013867","journal-title":"Kidney Int"},{"key":"3970_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1046\/j.1523-1755.2000.00140.x","volume":"58","author":"C Badid","year":"2000","unstructured":"Badid C, Vincent M, McGregor B, Melin M, Hadj-Aissa A, Veysseyre C, Hartmann DJ, Desmouliere A, Laville M (2000) Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney. Kidney Int 58:51\u201361","journal-title":"Kidney Int"},{"key":"3970_CR14","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1177\/0961203313480398","volume":"22","author":"CC Cheng","year":"2013","unstructured":"Cheng CC, Lee YF, Lan JL, Wu MJ, Hsieh TY, Lin NN, Wang JM, Chiu YT (2013) Mycophenolate mofetil alleviates lupus nephritis through urokinase receptor signaling in a mice model. Lupus 22:554\u2013561","journal-title":"Lupus"},{"key":"3970_CR15","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s00467-016-3437-y","volume":"32","author":"A Hackl","year":"2017","unstructured":"Hackl A, Ehren R, Weber LT (2017) Effect of mycophenolic acid in experimental, nontransplant glomerular diseases: new mechanisms beyond immune cells. Pediatr Nephrol 32:1315\u20131322","journal-title":"Pediatr Nephrol"},{"key":"3970_CR16","doi-asserted-by":"publisher","first-page":"E19","DOI":"10.1111\/j.1399-3046.2010.01437.x","volume":"15","author":"SC Weber","year":"2011","unstructured":"Weber SC, Uhlenberg B, Raile K, Querfeld U, Muller D (2011) Polyoma virus-associated progressive multifocal leukoencephalopathy after renal transplantation: regression following withdrawal of mycophenolate mofetil. Pediatr Transplant 15:E19\u2013E24","journal-title":"Pediatr Transplant"},{"key":"3970_CR17","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1097\/TP.0b013e31818b62c8","volume":"86","author":"RT Neff","year":"2008","unstructured":"Neff RT, Hurst FP, Falta EM, Bohen EM, Lentine KL, Dharnidharka VR, Agodoa LY, Jindal RM, Yuan CM, Abbott KC (2008) Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation. Transplantation 86:1474\u20131478","journal-title":"Transplantation"},{"key":"3970_CR18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ejmg.2016.09.014","volume":"60","author":"A Perez-Aytes","year":"2017","unstructured":"Perez-Aytes A, Marin-Reina P, Boso V, Ledo A, Carey JC, Vento M (2017) Mycophenolate mofetil embryopathy: a newly recognized teratogenic syndrome. Eur J Med Genet 60:16\u201321","journal-title":"Eur J Med Genet"},{"issue":"10","key":"3970_CR19","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1007\/s00467-017-3780-7","volume":"33","author":"Markus J. Kemper","year":"2017","unstructured":"Kemper MJ, Valentin L, van Husen M (2017) Difficult-to-treat idiopathic nephrotic syndrome: established drugs, open questions and future options. Pediatr Nephrol. https:\/\/doi.org\/10.1007\/s00467-017-3780-7","journal-title":"Pediatric Nephrology"},{"key":"3970_CR20","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1681\/ASN.2015050523","volume":"27","author":"M Colucci","year":"2016","unstructured":"Colucci M, Carsetti R, Cascioli S, Casiraghi F, Perna A, Rava L, Ruggiero B, Emma F, Vivarelli M (2016) B cell reconstitution after rituximab treatment in idiopathic nephrotic syndrome. J Am Soc Nephrol 27:1811\u20131822","journal-title":"J Am Soc Nephrol"},{"key":"3970_CR21","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1007\/s00467-008-0899-6","volume":"23","author":"EM Dorresteijn","year":"2008","unstructured":"Dorresteijn EM, Kist-van Holthe JE, Levtchenko EN, Nauta J, Hop WC, van der Heijden AJ (2008) Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. Pediatr Nephrol 23:2013\u20132020","journal-title":"Pediatr Nephrol"},{"key":"3970_CR22","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1681\/ASN.2012121200","volume":"24","author":"J Gellermann","year":"2013","unstructured":"Gellermann J, Weber L, Pape L, Tonshoff B, Hoyer P, Querfeld U (2013) Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome. J Am Soc Nephrol 24:1689\u20131697","journal-title":"J Am Soc Nephrol"},{"key":"3970_CR23","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.kint.2017.01.019","volume":"92","author":"A Sinha","year":"2017","unstructured":"Sinha A, Gupta A, Kalaivani M, Hari P, Dinda AK, Bagga A (2017) Mycophenolate mofetil is inferior to tacrolimus in sustaining remission in children with idiopathic steroid-resistant nephrotic syndrome. Kidney Int 92:248\u2013257","journal-title":"Kidney Int"},{"key":"3970_CR24","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1053\/j.ajkd.2003.08.011","volume":"42","author":"A Bagga","year":"2003","unstructured":"Bagga A, Hari P, Moudgil A, Jordan SC (2003) Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome. Am J Kidney Dis 42:1114\u20131120","journal-title":"Am J Kidney Dis"},{"key":"3970_CR25","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s00467-005-1957-y","volume":"20","author":"I Novak","year":"2005","unstructured":"Novak I, Frank R, Vento S, Vergara M, Gauthier B, Trachtman H (2005) Efficacy of mycophenolate mofetil in pediatric patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol 20:1265\u20131268","journal-title":"Pediatr Nephrol"},{"key":"3970_CR26","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.2215\/CJN.00550206","volume":"1","author":"RJ Hogg","year":"2006","unstructured":"Hogg RJ, Fitzgibbons L, Bruick J, Bunke M, Ault B, Baqi N, Trachtman H, Swinford R (2006) Mycophenolate mofetil in children with frequently relapsing nephrotic syndrome: a report from the Southwest Pediatric Nephrology Study Group. Clin J Am Soc Nephrol 1:1173\u20131178","journal-title":"Clin J Am Soc Nephrol"},{"key":"3970_CR27","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/j.1442-200X.2007.02487.x","volume":"49","author":"M Okada","year":"2007","unstructured":"Okada M, Sugimoto K, Yagi K, Yanagida H, Tabata N, Takemura T (2007) Mycophenolate mofetil therapy for children with intractable nephrotic syndrome. Pediatr Int 49:933\u2013937","journal-title":"Pediatr Int"},{"key":"3970_CR28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00467-006-0294-0","volume":"22","author":"S Fujinaga","year":"2007","unstructured":"Fujinaga S, Ohtomo Y, Umino D, Takemoto M, Shimizu T, Yamashiro Y, Kaneko K (2007) A prospective study on the use of mycophenolate mofetil in children with cyclosporine-dependent nephrotic syndrome. Pediatr Nephrol 22:71\u201376","journal-title":"Pediatr Nephrol"},{"key":"3970_CR29","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1007\/s00467-007-0617-9","volume":"22","author":"K Afzal","year":"2007","unstructured":"Afzal K, Bagga A, Menon S, Hari P, Jordan SC (2007) Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome. Pediatr Nephrol 22:2059\u20132065","journal-title":"Pediatr Nephrol"},{"key":"3970_CR30","first-page":"268","volume":"72","author":"S Fujinaga","year":"2009","unstructured":"Fujinaga S, Ohtomo Y, Hirano D, Nishizaki N, Someya T, Ohtsuka Y, Kaneko K, Shimizu T (2009) Mycophenolate mofetil therapy for childhood-onset steroid dependent nephrotic syndrome after long-term cyclosporine: extended experience in a single center. Clin Nephrol 72:268\u2013273","journal-title":"Clin Nephrol"},{"key":"3970_CR31","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00467-011-2006-7","volume":"27","author":"V Baudouin","year":"2012","unstructured":"Baudouin V, Alberti C, Lapeyraque AL, Bensman A, Andre JL, Broux F, Cailliez M, Decramer S, Niaudet P, Deschenes G, Jacqz-Aigrain E, Loirat C (2012) Mycophenolate mofetil for steroid-dependent nephrotic syndrome: a phase II Bayesian trial. Pediatr Nephrol 27:389\u2013396","journal-title":"Pediatr Nephrol"},{"key":"3970_CR32","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00467-012-2278-6","volume":"28","author":"S Banerjee","year":"2013","unstructured":"Banerjee S, Pahari A, Sengupta J, Patnaik SK (2013) Outcome of severe steroid-dependent nephrotic syndrome treated with mycophenolate mofetil. Pediatr Nephrol 28:93\u201397","journal-title":"Pediatr Nephrol"},{"key":"3970_CR33","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/nep.12537","volume":"21","author":"J Wang","year":"2016","unstructured":"Wang J, Mao J, Chen J, Fu H, Shen H, Zhu X, Liu A, Shu Q, Du L (2016) Evaluation of mycophenolate mofetil or tacrolimus in children with steroid sensitive but frequently relapsing or steroid-dependent nephrotic syndrome. Nephrology (Carlton) 21:21\u201327","journal-title":"Nephrology (Carlton)"},{"key":"3970_CR34","first-page":"221","volume":"94","author":"M Jellouli","year":"2016","unstructured":"Jellouli M, Fitouhi S, Abidi K, Hammi Y, Naija O, Zarrouk C, Gargah T (2016) Mycophenolate mofetil in treatment of childhood steroid-dependent nephrotic syndrome. Tunis Med 94:221\u2013225","journal-title":"Tunis Med"},{"key":"3970_CR35","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s10157-016-1266-8","volume":"21","author":"B Basu","year":"2017","unstructured":"Basu B, Babu BG, Mahapatra TK (2017) Long-term efficacy and safety of common steroid-sparing agents in idiopathic nephrotic children. Clin Exp Nephrol 21:143\u2013151","journal-title":"Clin Exp Nephrol"},{"key":"3970_CR36","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s00467-003-1175-4","volume":"18","author":"GM Barletta","year":"2003","unstructured":"Barletta GM, Smoyer WE, Bunchman TE, Flynn JT, Kershaw DB (2003) Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome. Pediatr Nephrol 18:833\u2013837","journal-title":"Pediatr Nephrol"},{"key":"3970_CR37","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1007\/s00467-003-1174-5","volume":"18","author":"B Montane","year":"2003","unstructured":"Montane B, Abitbol C, Chandar J, Strauss J, Zilleruelo G (2003) Novel therapy of focal glomerulosclerosis with mycophenolate and angiotensin blockade. Pediatr Nephrol 18:772\u2013777","journal-title":"Pediatr Nephrol"},{"key":"3970_CR38","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s00467-003-1300-4","volume":"19","author":"J Gellermann","year":"2004","unstructured":"Gellermann J, Querfeld U (2004) Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil. Pediatr Nephrol 19:101\u2013104","journal-title":"Pediatr Nephrol"},{"key":"3970_CR39","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1007\/s00467-004-1778-4","volume":"20","author":"T Ulinski","year":"2005","unstructured":"Ulinski T, Dubourg L, Said MH, Parchoux B, Ranchin B, Cochat P (2005) Switch from cyclosporine A to mycophenolate mofetil in nephrotic children. Pediatr Nephrol 20:482\u2013485","journal-title":"Pediatr Nephrol"},{"key":"3970_CR40","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1007\/s00467-005-1877-x","volume":"20","author":"S Mendizabal","year":"2005","unstructured":"Mendizabal S, Zamora I, Berbel O, Sanahuja MJ, Fuentes J, Simon J (2005) Mycophenolate mofetil in steroid\/cyclosporine-dependent\/resistant nephrotic syndrome. Pediatr Nephrol 20:914\u2013919","journal-title":"Pediatr Nephrol"},{"key":"3970_CR41","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00467-009-1356-x","volume":"25","author":"VR Mello de","year":"2010","unstructured":"de Mello VR, Rodrigues MT, Mastrocinque TH, Martins SP, de Andrade OV, Guidoni EB, Scheffer DK, Martini Filho D, Toporovski J, Benini V (2010) Mycophenolate mofetil in children with steroid\/cyclophosphamide-resistant nephrotic syndrome. Pediatr Nephrol 25:453\u2013460","journal-title":"Pediatr Nephrol"},{"key":"3970_CR42","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s00467-009-1375-7","volume":"25","author":"Z Li","year":"2010","unstructured":"Li Z, Duan C, He J, Wu T, Xun M, Zhang Y, Yin Y (2010) Mycophenolate mofetil therapy for children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 25:883\u2013888","journal-title":"Pediatr Nephrol"},{"key":"3970_CR43","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1093\/ckj\/sft071","volume":"6","author":"AV Hassan","year":"2013","unstructured":"Hassan AV, Sinha MD, Waller S (2013) A single-centre retrospective study of the safety and efficacy of mycophenolate mofetil in children and adolescents with nephrotic syndrome. Clin Kidney J 6:384\u2013389","journal-title":"Clin Kidney J"},{"key":"3970_CR44","doi-asserted-by":"publisher","first-page":"380","DOI":"10.5144\/0256-4947.2005.380","volume":"25","author":"S Al-Akash","year":"2005","unstructured":"Al-Akash S, Al-Makdama A (2005) Mycophenolate mofetil in children with steroid-dependent and\/or frequently relapsing nephrotic syndrome. Ann Saudi Med 25:380\u2013384","journal-title":"Ann Saudi Med"},{"key":"3970_CR45","doi-asserted-by":"publisher","first-page":"203","DOI":"10.5301\/JN.2011.6327","volume":"24","author":"TT Gargah","year":"2011","unstructured":"Gargah TT, Lakhoua MR (2011) Mycophenolate mofetil in treatment of childhood steroid-resistant nephrotic syndrome. J Nephrol 24:203\u2013207","journal-title":"J Nephrol"},{"key":"3970_CR46","first-page":"346","volume":"6","author":"A Nickavar","year":"2012","unstructured":"Nickavar A, Safarzadeh AE, Sotoudeh K, Otukesh H, Hooman N (2012) Mycophenolate mofetil for treatment of idiopathic nephrotic syndrome in children. Iran J Kidney Dis 6:346\u2013349","journal-title":"Iran J Kidney Dis"},{"key":"3970_CR47","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00431-012-1913-3","volume":"172","author":"S Fujinaga","year":"2013","unstructured":"Fujinaga S, Someya T, Watanabe T, Ito A, Ohtomo Y, Shimizu T, Kaneko K (2013) Cyclosporine versus mycophenolate mofetil for maintenance of remission of steroid-dependent nephrotic syndrome after a single infusion of rituximab. Eur J Pediatr 172:513\u2013518","journal-title":"Eur J Pediatr"},{"key":"3970_CR48","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1007\/s00467-011-1886-x","volume":"26","author":"S Ito","year":"2011","unstructured":"Ito S, Kamei K, Ogura M, Sato M, Fujimaru T, Ishikawa T, Udagawa T, Iijima K (2011) Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol 26:1823\u20131828","journal-title":"Pediatr Nephrol"},{"key":"3970_CR49","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1093\/ndt\/gfr572","volume":"27","author":"J Gellermann","year":"2012","unstructured":"Gellermann J, Ehrich JH, Querfeld U (2012) Sequential maintenance therapy with cyclosporin A and mycophenolate mofetil for sustained remission of childhood steroid-resistant nephrotic syndrome. Nephrol Dial Transplant 27:1970\u20131978","journal-title":"Nephrol Dial Transplant"},{"key":"3970_CR50","doi-asserted-by":"publisher","first-page":"930965","DOI":"10.4061\/2011\/930965","volume":"2011","author":"AA Nikibakhsh","year":"2011","unstructured":"Nikibakhsh AA, Mahmoodzadeh H, Karamyyar M, Hejazi S, Noroozi M, Macooie AA (2011) Treatment of steroid and cyclosporine-resistant idiopathic nephrotic syndrome in children. Int J Nephrol 2011:930965","journal-title":"Int J Nephrol"},{"key":"3970_CR51","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/ped.12498","volume":"57","author":"S Hibino","year":"2015","unstructured":"Hibino S, Uemura O, Nagai T, Yamakawa S, Iwata N, Ito H, Nakano M, Tanaka K (2015) Three year outcome of childhood idiopathic nephrotic syndrome under a unified immunosuppressive protocol. Pediatr Int 57:85\u201391","journal-title":"Pediatr Int"},{"key":"3970_CR52","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/nep.12351","volume":"20","author":"B Wu","year":"2015","unstructured":"Wu B, Mao J, Shen H, Fu H, Wang J, Liu A, Gu W, Shu Q, Du L (2015) Triple immunosuppressive therapy in steroid-resistant nephrotic syndrome children with tacrolimus resistance or tacrolimus sensitivity but frequently relapsing. Nephrology (Carlton) 20:18\u201324","journal-title":"Nephrology (Carlton)"},{"key":"3970_CR53","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000357355","volume":"4","author":"J Kim","year":"2014","unstructured":"Kim J, Patnaik N, Chorny N, Frank R, Infante L, Sethna C (2014) Second-line immunosuppressive treatment of childhood nephrotic syndrome: a single-center experience. Nephron Extra 4:8\u201317","journal-title":"Nephron Extra"},{"key":"3970_CR54","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/j.1399-3046.2005.00335.x","volume":"9","author":"B Hocker","year":"2005","unstructured":"Hocker B, Weber LT, Bunchman T, Rashford M, Tonshoff B, Tricontinental MMFSSG (2005) Mycophenolate mofetil suspension in pediatric renal transplantation: three-year data from the tricontinental trial. Pediatr Transplant 9:504\u2013511","journal-title":"Pediatr Transplant"},{"key":"3970_CR55","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00467-014-2813-8","volume":"30","author":"LT Weber","year":"2015","unstructured":"Weber LT (2015) Therapeutic drug monitoring in pediatric renal transplantation. Pediatr Nephrol 30:253\u2013265","journal-title":"Pediatr Nephrol"},{"key":"3970_CR56","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00467-016-3352-2","volume":"32","author":"G Filler","year":"2017","unstructured":"Filler G, Alvarez-Elias AC, McIntyre C, Medeiros M (2017) The compelling case for therapeutic drug monitoring of mycophenolate mofetil therapy. Pediatr Nephrol 32:21\u201329","journal-title":"Pediatr Nephrol"},{"key":"3970_CR57","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2217\/pgs.10.9","volume":"11","author":"KA Barraclough","year":"2010","unstructured":"Barraclough KA, Lee KJ, Staatz CE (2010) Pharmacogenetic influences on mycophenolate therapy. Pharmacogenomics 11:369\u2013390","journal-title":"Pharmacogenomics"},{"key":"3970_CR58","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2215\/CJN.07111009","volume":"5","author":"DR Kuypers","year":"2010","unstructured":"Kuypers DR, Le Meur Y, Cantarovich M, Tredger MJ, Tett SE, Cattaneo D, Tonshoff B, Holt DW, Chapman J, Gelder T, Transplantation Society Consensus Group on TDMoMPA (2010) Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol 5:341\u2013358","journal-title":"Clin J Am Soc Nephrol"},{"key":"3970_CR59","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ejps.2015.06.017","volume":"77","author":"J Sobiak","year":"2015","unstructured":"Sobiak J, Resztak M, Ostalska-Nowicka D, Zachwieja J, Gasiorowska K, Piechanowska W, Chrzanowska M (2015) Monitoring of mycophenolate mofetil metabolites in children with nephrotic syndrome and the proposed novel target values of pharmacokinetic parameters. Eur J Pharm Sci 77:189\u2013196","journal-title":"Eur J Pharm Sci"},{"key":"3970_CR60","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1159\/000445070","volume":"132","author":"K Tong","year":"2016","unstructured":"Tong K, Mao J, Fu H, Shen H, Liu A, Shu Q, Du L (2016) The value of monitoring the serum concentration of mycophenolate mofetil in children with steroid-dependent\/frequent relapsing nephrotic syndrome. Nephron 132:327\u2013334","journal-title":"Nephron"},{"key":"3970_CR61","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/FTD.0000000000000258","volume":"38","author":"A Hackl","year":"2016","unstructured":"Hackl A, Cseprekal O, Gessner M, Liebau MC, Habbig S, Ehren R, Muller C, Taylan C, Dotsch J, Weber LT (2016) Mycophenolate mofetil therapy in children with idiopathic nephrotic syndrome: does therapeutic drug monitoring make a difference? Ther Drug Monit 38:274\u2013279","journal-title":"Ther Drug Monit"},{"key":"3970_CR62","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1097\/01.ASN.0000027031.79843.6C","volume":"13","author":"LT Weber","year":"2002","unstructured":"Weber LT, Shipkova M, Armstrong VW, Wagner N, Schutz E, Mehls O, Zimmerhackl LB, Oellerich M, Tonshoff B (2002) The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy. J Am Soc Nephrol 13:759\u2013768","journal-title":"J Am Soc Nephrol"},{"key":"3970_CR63","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1097\/00007691-200110000-00003","volume":"23","author":"G Filler","year":"2001","unstructured":"Filler G, Lepage N, Delisle B, Mai I (2001) Effect of cyclosporine on mycophenolic acid area under the concentration-time curve in pediatric kidney transplant recipients. Ther Drug Monit 23:514\u2013519","journal-title":"Ther Drug Monit"},{"key":"3970_CR64","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.phrs.2011.01.009","volume":"63","author":"F Saint-Marcoux","year":"2011","unstructured":"Saint-Marcoux F, Guigonis V, Decramer S, Gandia P, Ranchin B, Parant F, Bessenay L, Libert F, Harambat J, Bouchet S, Broux F, Compagnon P, Marquet P (2011) Development of a Bayesian estimator for the therapeutic drug monitoring of mycophenolate mofetil in children with idiopathic nephrotic syndrome. Pharmacol Res 63:423\u2013431","journal-title":"Pharmacol Res"},{"key":"3970_CR65","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1177\/0091270009357429","volume":"50","author":"W Zhao","year":"2010","unstructured":"Zhao W, Fakhoury M, Deschenes G, Roussey G, Brochard K, Niaudet P, Tsimaratos M, Andre JL, Cloarec S, Cochat P, Bensman A, Azougagh S, Jacqz-Aigrain E (2010) Population pharmacokinetics and pharmacogenetics of mycophenolic acid following administration of mycophenolate mofetil in de novo pediatric renal-transplant patients. J Clin Pharmacol 50:1280\u20131291","journal-title":"J Clin Pharmacol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-018-3970-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-018-3970-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-018-3970-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T05:30:51Z","timestamp":1661232651000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-018-3970-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,11]]},"references-count":65,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3970"],"URL":"https:\/\/doi.org\/10.1007\/s00467-018-3970-y","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,11]]},"assertion":[{"value":"23 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Uwe Querfeld declares that he has no conflict of interest. Lutz T. Weber has received financial support (travel grants) from Astellas.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}